A Phase 1 Study To Assess The Effect Of Moderate Renal Impairment On The Pharmacokinetics Of Surufatinib
Latest Information Update: 27 Oct 2021
At a glance
- Drugs Surufatinib (Primary)
- Indications Biliary cancer; Neuroendocrine tumours; Soft tissue sarcoma; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma; HUTCHMED
- 20 Oct 2021 Status changed from recruiting to completed.
- 20 May 2021 Status changed from not yet recruiting to recruiting.
- 16 Feb 2021 New trial record